53rd week of 2009 patent applcation highlights part 44 |
Patent application number | Title | Published |
20090324477 | METHOD FOR PRODUCING TRICHLOROSILANE AND APPARATUS FOR PRODUCING TRICHLOROSILANE - An apparatus comprising: a reaction chamber | 2009-12-31 |
20090324478 | Method for Making Silicon-Containing Products - A method for producing carbon-silica products from silica-containing plant matter such as rice hulls or straw by leaching with sulfuric acid to remove non-silica minerals and metal while adjusting the mole ratio of fixed carbon to silica in the resultant product. The carbon and silica are intimately mixed on a micron or submicron scale and are characterized by high purity and reactivity, small particle size, high porosity, and contain volatile carbon that can be used as a source of energy for the production of silicon-containing products from the carbon-silica products. High purity silicon-containing products made from the carbon-silica products of the invention are also disclosed. | 2009-12-31 |
20090324479 | FLUIDIZED BED REACTOR SYSTEMS AND METHODS FOR REDUCING THE DEPOSITION OF SILICON ON REACTOR WALLS - Gas distribution units of fluidized bed reactors are configured to direct thermally decomposable compounds to the center portion of the reactor and away from the reactor wall to prevent deposition of material on the reactor wall and process for producing polycrystalline silicon product in a reactor that reduce the amount of silicon which deposits on the reactor wall. | 2009-12-31 |
20090324480 | Method for manufacturing hydroxylamine - Provided is a method for manufacturing hydroxylamine. In this method, an aqueous reaction medium containing acidic buffer agent and nitrate ions in the presence of a limited amount of metal impurities such as Fe or Cu is introduced into a hydroxylamine synthesis reactor in the presence of catalyst to proceed hydroxylamine synthesis by reduction of nitrate ions with hydrogen gas as reducing agent in the aqueous reaction medium to produce hydroxylamine. The reaction is processed in the aqueous reaction medium with a limited amount of metal impurities or even without metal impurities, such that the selection rate of the hydroxylamine product is increased. | 2009-12-31 |
20090324481 | LOW ENERGY METHOD OF PREPARING BASIC COPPER CARBONATES - A method of forming basic copper carbonates includes providing an aqueous solution comprising copper (II) ammonia, and carbonic acid; and adding sufficient carbon dioxide to precipitate a basic copper carbonate from the aqueous solution. | 2009-12-31 |
20090324482 | LOW ENERGY METHOD OF PREPARING BASIC COPPER CARBONATES - A method of forming basic copper carbonates includes providing an aqueous solution comprising copper (II), ammonia, and carbonic acid; and adding sufficient carbon dioxide to precipitate a basic copper carbonate from the aqueous solution. | 2009-12-31 |
20090324483 | Separation of carbon nanotubes into chirally enriched fractions - A mixture of single-walled carbon nanotubes (“SWNTs”) is separated into fractions of enriched chirality by preparing an aqueous suspension of a mixture of SWNTs and a surfactant, injecting a portion of the suspension on a column of separation medium having a density gradient, and centrifuging the column. In some embodiments, salt is added prior to centrifugation. In other embodiments, the centrifugation is performed at a temperature below room temperature. Fractions separate as colored bands in the column. The diameter of the separated SWNTs decreases with increasing density along the gradient of the column. The colored bands can be withdrawn separately from the column. | 2009-12-31 |
20090324484 | Effect Of Hydrocarbon And Transport Gas Feedstock On Efficiency And Quality Of Grown Single-Walled Nanotubes - Methods and processes for synthesizing high quality carbon single-walled nanotubes (SWNTs) are provided. The method provides the means for optimization of amount of carbon precursor and transport gas per unit weight of catalyst. Efficiencies of about 20% can be achieved when contacting the catalyst deposited on a support with a carbon precursor gas with a flow rates of about 4.2×10 | 2009-12-31 |
20090324485 | HIGH PURITY NUCLEAR GRAPHITE - A highly isotropic graphite useful for, inter alia, nuclear applications is disclosed, which has a ash content of less than 300 ppm and a boron equivalence of less than about 2 ppm without requiring a post graphitization purification step. | 2009-12-31 |
20090324486 | Fabrication of NiO nanoparticles and chip-like nanoflakes by solvothermal technique - A method is disclosed for fabrication of NiO nanoparticles and NiO chip-like nanoflakes by solvothermal technique. Mixed organic alcohols were used as solvent to make a homogenous solution from a nickel containing salt (or complex) for production of NiO nanoparticles and chip-like nanoflakes. The solution was heated in a sealed flask sitting inside a warm furnace. The precipitate was filtered, rinsed, dried and calcined to produce nanoparticles or nanoflakes. The size of the particles was controllable by heating time and temperature. Similar procedures were used for production of both nanostructures except hydrogen peroxide addition to the initial solution for NiO chip-like nanoflakes fabrication. | 2009-12-31 |
20090324487 | Method for preparing iron oxides - Highly pure iron oxides are prepared by reaction of metallic iron, in the form of microspheroidal particles or of scraps or cuttings, with an agitated aqueous solution of a mono- or polycarboxylic acid with a pKa of 0.5 to 6 relative to the first carboxyl and capable of decomposing, by heating in air at 200 to 350° C., to carbon dioxide and water, using 0.03 to 1.5 moles of acid per g-atoms of iron, a water/iron weight ration of 1 to 20, and by oxidation of the ferrous carboxilate to ferric salt, with an agent selected from oxygen, mixtures containing oxygen, hydrogen peroxide, organic peroxides and hydroperoxides. | 2009-12-31 |
20090324488 | System and method for on-board waste heat recovery - A technique is described including receiving a hydrocarbon stream, and heating the hydrocarbon stream with an exhaust steam from an internal combustion engine. This technique may include reacting the hydrocarbon stream catalytically to produce hydrogen and a modified hydrocarbon stream having a lower saturation state than the hydrocarbon stream, recovering energy from the hydrogen stream, and/or providing the modified hydrocarbon stream to a fuel supply for the internal combustion engine. | 2009-12-31 |
20090324489 | Wortmannin conjugates and uses thereof - The invention features conjugates of wortmannin, and wortmannin derivatives, and their use as inhibitors of PI3-kinase activity in treating cancer, inflammatory diseases, and | 2009-12-31 |
20090324490 | Compositions and methods for the diagnosis and treatment of tumor - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 2009-12-31 |
20090324491 | Diagnosis and Treatment of Cancer Using Anti-EREG Antibody - Methods that entail detection of an epiregulin (EREG) protein for cancer diagnosis are disclosed. In colon cancer, lung adenocarcinoma, pancreatic cancer, stomach cancer, and kidney cancer, the gene and protein expressions of EREG were frequently found to be elevated. Antibodies that recognize an EREG protein are used for diagnosing or treating cancer in the present invention. Pharmaceutical compositions, cell proliferation inhibitors, and anticancer agents containing an EREG-binding antibody as an active ingredient are also disclosed. Methods of inducing cell damage in EREG-expressing cells and methods of suppressing the proliferation of EREG-expressing cells by contacting the EREG-expressing cells with EREG-binding antibodies are also disclosed. | 2009-12-31 |
20090324492 | Treatment for Central Nervous System Disorders - Compositions that include an Aβ polypeptide linked to a non-Aβ polypeptide are described, as well as methods of using such compositions. | 2009-12-31 |
20090324493 | METHOD FOR PREPARING A SALINE SOLUTION COMPRISING [13N] NH4 + AND USE OF A DEVICE - The invention relates to a method for preparing a saline solution comprising [13N]NH4+. The method comprises following steps: preparing [13N]NH3 gas, transporting [13N]NH3 gas to a diffusion chamber, to a first side of a semipermeable membrane, transporting sterile saline solution to the diffusion chamber, to a second side of a semipermeable membrane, allowing the mixing of [13N]NH3 gas that has penetrated the semipermeable membrane with the saline solution on the second side of the semipermeable membrane, whereby saline solution comprising [13N]NH4+ is obtained, and directing the saline solution comprising [13N]NH4+ out from the diffusion chamber. The invention relates also to use of a device for preparing a radiolabelled saline solution for preparation of a saline solution comprising [13N]NH4+. | 2009-12-31 |
20090324494 | MAGNETIC NANO-COMPOSITE FOR CONTRAST AGENT, INTELLIGENT CONTRAST AGENT, DRUG DELIVERY AGENT FOR SIMULTANEOUS DIAGNOSIS AND TREATMENT, AND SEPARATION AGENT FOR TARGET SUBSTANCE - The present invention relates to water soluble magnetic nanocomposite using an amphiphilic compound. Specifically, the present invention relates to water soluble magnetic nanocomposite which may be not only used as a contrast agent for magnetic resonance imaging (MRI), an intelligent contrast agent for diagnosing cancer characterized by binding a tissue-specific binder ingredient, a drug delivery system for simultaneous diagnosis and treatment by polymerizing or enveloping drugs and binding a tissue-specific binder ingredient, but also used for separating a target substance using magnetism, and a process for preparing the same. | 2009-12-31 |
20090324495 | COMPOUNDS AND METHODS FOR ENZYME-MEDIATED TUMOR IMAGING AND THERAPY - The invention provides methods and compositions, e.g., for tumor imaging and therapy. | 2009-12-31 |
20090324496 | Radioactive material for inhibiting cancer and preparation method thereof - A radioactive material for inhibiting cancer and a preparation method thereof are disclosed. The radioactive material for inhibiting cancer is M-SOCTA-Z and M is a radioactive nuclide such as | 2009-12-31 |
20090324497 | Tc and Re Labeled Radioactive Glycosylated Octreotide Derivatives - Improved sst-receptor binding peptidic ligands for diagnostic and therapeutic applications in nuclear medicine are provided. The improved ligands contain either natural or unnatural amino acids or peptidomimetic structures that are modified at either the N-terminal or the C-terminal end or at both termini, a carbohydrate unit and a chelator or prosthetic group to provide a complexation of a radioisotope binding or holding the radioisotope. The sst- or SSTR-receptor binding peptidic ligands may also contain one or more multifunctional linker units optionally coupling the peptide, and/or the sugar moiety and/or the chelator and/or the prosthetic group. Upon administering the ligand to a mammal through the blood system the ligand provides improved availability, clearance kinetics, sst-receptor targeting and internalization over the non-carbohydrated ligands. | 2009-12-31 |
20090324498 | METHOD OF MEASURING QUANTITY OF IN-VIVO SUBSTANCE BY USE OF COHERENT ANTI-STOKES RAMAN SCATTERED LIGHT - A method of measuring the quantity of an in-vivo substance includes the steps of: irradiating an in-vivo substance with two near infrared femtosecond laser beams of different frequencies; detecting coherent anti-Stokes Raman scattered light emitted from the in-vivo substance due to coincidence of the frequency difference between the two near infrared femtosecond laser beams with a natural frequency of the in-vivo substance; and determining the quantity of the in-vivo substance, based on a peak intensity of a Raman scattering spectrum obtained. | 2009-12-31 |
20090324499 | VITAMIN-TARGETED IMAGING AGENTS - The invention relates to compounds and methods for targeting radionuclide-based imaging agents to cells having receptors for a vitamin, or vitamin receptor binding derivative or analog thereof, by using such a vitamin as the targeting ligand for the imaging agent. The invention provides a compound of the formula | 2009-12-31 |
20090324500 | SCREEN FOR INFLAMMATORY RESPONSE MODULATORS - The present invention relates to transgenic aquatic vertebrate organisms and methods of their use in screening for, or identifying agents that are useful in modulating the inflammatory response and particularly for identifying agents useful for treating inflammatory disorders. | 2009-12-31 |
20090324501 | Vaccine Carrier - The present invention relates to a hypoallergenic protein consisting of at least one hypoallergenic molecule derived from an allergen, which is fused or conjugated to at least one second non-allergenic protein or fragment thereof. | 2009-12-31 |
20090324502 | Nasal Formulations of Insulin - The present invention provides a method for achieving a therapeutically effective plasma levels of insulin by administering at least two doses of pharmaceutical formulation of insulin sequentially into the same nostril. The administration of the second dose in the same nostril gives substantially higher plasma levels of insulin when compared with sequential administration in two different nostrils. Without being limited to any specific physiological mechanism, it is believed that the first dose of insulin acts as a loading dose. This loading dose is required to achieve the subsequent plasma levels of insulin that are observed with subsequent doses. The Cmax of plasma insulin achieved by the methods and formulations of the present invention is at least about 70 microU/ml when plasma insulin is measured from about 0 to about 45 minutes after administration of a second dose. The AUC achieved is at least about 1800 microU/(ml*min). When administered sequentially in the same nostril, the Cmax of plasma insulin after a second dose is about five-fold greater than the Cmax of plasma insulin observed after the first dose; note, plasma insulin is measured from about 0 to about 45 minutes after administration of a second dose. | 2009-12-31 |
20090324503 | METHODS FOR DETECTING A MYCOBACTERIUM TUBERCULOSIS INFECTION - Methods for detecting an infection with | 2009-12-31 |
20090324504 | Method for delivering liquid active agents for deodorising and disinfecting an enclosed space, in particular an animal enclosure - A method is described for delivering liquid active agents for deodorising and disinfecting an enclosed space ( | 2009-12-31 |
20090324505 | Surfactant gas pressurized liquid composition and method and package for delivering - A self gassing composition comprising at least one surfactant and a fermentation base including a gas producing organism and at least one sugar is disclosed. Use of a nonionic surfactant in the self gassing composition allows the fermentation base to continue reacting and producing gas. Additionally, a personal care cleansing product and method for storing and delivering an aqueous composition having at least one surfactant and pressurized gas dissolved therein is disclosed. In one aspect, the composition is stored in an internal reservoir in a container such that when a sealing device is removed from a valveless opening, the composition foams and plumes out the opening of the container as the gas dissolved in the composition is released. In addition to the self gassing composition, a pressurized gas may be injected into a surfactant composition to produce the gas pressurized cleaning composition. | 2009-12-31 |
20090324506 | Sprayable skin protectant formulation and method of use - The present disclosure is directed to a skin protectant formulation that is designed to be sprayed onto human skin for the purpose of protecting the skin. In particular, an exemplary formulation of the present disclosure contains at least a carrier, a structurant and a skin protectant agent. An exemplary formulation contains a carrier comprising at least water, a structurant comprising at least a laponite clay, and a skin protectant agent comprising petrolatum. Typically, the skin protectant formulation will comprise at least about 30 wt. % of a skin protectant agent. A continuous spray dispenser may be used to apply the skin protectant formulation to reduce the need for rubbing as the treated area can be covered by a mist of the skin protectant formulation requiring no need to rub for application or small droplets that do not require extensive time for rubbing in. | 2009-12-31 |
20090324507 | RNAi-Mediated Inhibition of Spleen Tyrosine Kinase-Related Inflammatory Conditions - RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease. | 2009-12-31 |
20090324508 | Broad Spectrum and Skin Friendly Disinfecting Composition - The present invention discloses a composition for use in a foam dispenser comprising: 0.1-5% (w/w) hydrogen peroxide, 21-55% (w/w) of a C2-C6 alcohol, and 0.01-2% (w/w) of a foam booster. The foam booster is capable of providing a stable foam when dispensing a composition consisting of 36% (w/w) ethanol and 0.2% (w/w) of the foam booster from a foam dispenser. The composition provided as a foam is suitable for disinfecting skin and/or mucous membranes. | 2009-12-31 |
20090324509 | INSECTICIDAL COMPOSITION - A pesticidal composition which comprises cymene and either a pyrethrin insecticide or an insect growth regulator. In particular the composition is formulated as an aerosol for killing or controlling pests and in particular flying pests. | 2009-12-31 |
20090324510 | DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES - The present invention relates to novel drug combinations which, besides one or more, preferably on compound of the general formula (1), wherein remainder n, A, R1, R2, and R3 can have the meanings given in the claims and in the description comprise at least one further active ingredient 2 and method for the production thereof and the use thereof as drugs. | 2009-12-31 |
20090324511 | Compounds, Compositions and Methods - Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | 2009-12-31 |
20090324512 | POLYPEPTIDE CONSTRUCTS FOR NASAL ADMINISTRATION - The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules. | 2009-12-31 |
20090324513 | Process for Producing Chlorinated Sucrose - Present invention relates to disclosure of application of some innovative techniques useful for substantially improving process efficiency of production of chlorinated sucrose including their intermediates and derivatives. Application of mild methods of drying has been made for recovery of chlorinated sucrose or their intermediates and derivatives, in substantially pure form or with other solid chemical impurities, obtained at various stages in the process of production of chlorinated sucrose. Mild methods of drying included agitated thin film drying, spray drying, freeze drying and super critical extraction. Use of alkoxides has been introduced for deacylation instead of alkali hydroxides or alkaline earth hydroxides. Deacylation has been shown to be effective both, either before or after drying of the reaction mixture. Extraction and purification of desired products i.e. of chlorinated sucrose or its intermediates or derivatives, from dried solid mixtures could be achieved by using appropriate extraction method, including but not limited to solvent extraction and super critical extraction. Further purification of such extracts can be done by crystallization or direct drying under mild conditions. | 2009-12-31 |
20090324514 | Methods and composition for treating a material - A composition and method are described for sanitizing or otherwise treating a material such as a non-living surface, living tissue, soil or atmosphere which may be contaminated by a toxin, chemical warfare agent, insect, prion, microorganism or other infectious agent. The composition generally includes an aqueous composition mixture that includes: (a) lower alkanol; (b) an alkalinating agent, and (c) a fatty acid salt and/or ester. The components are present in an effective amount to sanitize (or treat) a material (or modifying a chemical contained thereon) to which the composition is applied. Also described are methods of making the composition. | 2009-12-31 |
20090324515 | ANTIMICROBIAL FLAVOURING COMPOSITION - A flavouring composition for use in an oral care product, confectionary product or beverage. The composition includes an antimicrobial key and optionally at least one flavouring ingredient of current use, wherein the antimicrobial key comprises 3,4-dimethylphenol together with one or more antimicrobial flavour ingredients each having a minimum inhibitory concentration of 1000 parts per million or less, against two or more strains selected from | 2009-12-31 |
20090324516 | Composition and Method for Enhancing Flouride Uptake Using Bioactive Glass - A method for increasing fluoride uptake onto a tooth structure of a patient comprises contacting the tooth structure with an oral care composition, which comprises bioactive glass and fluoride. The oral care composition has the following formulation: | 2009-12-31 |
20090324517 | HALITOSIS TREATMENT - A method of oral treatment to eliminate odors, particularly halitosis, using two or more oral treatment compositions. A four step method in a sequential order may be followed using compositions including hydrogen peroxide, metal ions, bactericidal agents and essential oils. Gargling increases the effectiveness of the treatment. Good breath is maintained with a two step maintenance treatment. | 2009-12-31 |
20090324518 | Novel Compositions Against Alkyl-Acyul-GPC The Derivatitves and Products Thereof - The invention refers to novel compositions with at least one prehormone, hormone from group consisting of mevalonate derivatives or from the group consisting of peptides and/or proteo-hormones and at least one mineral, one constituent by preference from the group consisting of iodine, selen and at least one Ginkgoloide against alkyl-acyl-GPC (AAGPC), its derivatives (alkyl-lipis) and/or products (e.g. acetylacyl-CoA). In addition, the invention also refers to the manufacture of novel compositions with at least one Ginkgoloide and/or acetylcysteine for oral, dietary, oily or local, cosmetic administration. Novel local preparations without ether/volatile oils contain Ginkgoloides with at least one sun screening agent against impairments of pigmentation. | 2009-12-31 |
20090324519 | ESTERIFICATION REACTION PRODUCT, GELLING AGENT CONTAINING THE PRODUCT, AND COSMETIC PREPARATION CONTAINING THEM - Disclosed is an esterification reaction product which is capable of gelling both an oil agent and a cyclic silicone or a volatile dimethylpolysiloxane, or both an oil agent and a nonvolatile dimethylpolysiloxane. Also disclosed are a gelling agent contacting the esterification reaction product, and a cosmetic preparation containing the esterification reaction product or the gelling product and having an excellent feeling of use. Specifically, the cosmetic preparation contains, as a gelling agent, an esterification reaction product which is obtained by esterifying a component A that is a polyhydric alcohol or a condensate thereof, a component B that is a saturated dibasic acid having 10-28 carbon atoms, a component C that is a linear saturated fatty acid having 16-28 carbon atoms, and a component D that is a branched saturated fatty acid having 8-28 carbon atoms at a blending ratio (component A: component B) of 1.0 mole:0.10-0.20 mole. | 2009-12-31 |
20090324520 | PERSONAL-CARE ARTICLE FOR SEQUENTIALLY DISPENSING COMPOSITIONS WITH VARIABLE CONCENTRATIONS OF PARTITIONED BENEFIT OR SUSPENDED BENEFIT AGENTS - The present invention relates to a personal-care article comprising a package and a personal-care product. The package comprises at least one chamber, a dispensing orifice, a first zone proximate to the dispensing orifice, and a second zone distal to the dispensing orifice. The first zone and second zone are both located in at least one chamber. The personal-care product comprises a first personal-care composition substantially disposed within the first zone and a second personal-care composition substantially disposed within the second zone. The first composition comprises a first concentration of a partitioned benefit agent or a suspended benefit agent. The second composition comprises a benefit phase comprising a second concentration of a partitioned benefit agent or a suspended benefit agent. The first concentration is different from the second concentration. | 2009-12-31 |
20090324521 | Personal Care Article For Sequentially Dispensing Compositions With Variable Concentrations Of Hydrophobic Benefit Materials - The personal care article comprises a single chamber package and a personal care product. The package comprises a dispensing orifice, a first zone, a second zone and a third zone that are located proximal, medial and distal to the dispensing orifice. The personal care product comprises a first, a second and a third personal care composition with a first, second, and third concentration of hydrophobic benefit material. The first, second, and third personal care compositions are substantially within the first, second and third zones. The personal care product comprises a second concentration that is greater than the first and third concentration of hydrophobic benefit material. The personal care product is sequentially dispensed, such that, the first personal care composition is capable of being substantially dispensed prior to the second and third personal care compositions and the second is capable of being substantially dispensed prior to the third personal care composition. | 2009-12-31 |
20090324522 | SKIN PROTECTANT COMPOSITIONS - A topical composition for the protection of skin from damage caused by ultraviolet radiation. The composition includes a direct antioxidant and a phase 2 enzyme inducer (indirect antioxidant) in cosmetic and dermopharmaceutical compositions that protects and prevents skin damage and aging caused by UV radiation. In a particular embodiment, the composition includes a broccoli extract in combination with a composition including Hibiscus flower extract, Ferula Assa Foetida root extract, pear fruit extract, and green tea leaf extract, which exhibit a synergistic effect in protecting the skin from the adverse effects of ultraviolet radiation. In another embodiment, the composition further includes Vitamin C and Vitamin E. The antioxidant compositions can be incorporated into cosmetics, pharmaceutical compositions, sunscreen products, moisturizing lotions, skin toners, and other skin care products. | 2009-12-31 |
20090324523 | COMPOSITIONS COMPRISING AN ULTRAVIOLET RADIATION-ABSORBING POLYMER - Ultraviolet radiation-absorbing polymers having a first pendant group that comprises an ultraviolet radiation-absorbing moiety and a second pendant group that comprises at least one siloxane linkage and/or an intermediate length carbon chain are disclosed. Personal care compositions including the ultraviolet radiation-absorbing polymer are provided. | 2009-12-31 |
20090324524 | COMPOSITIONS COMPRISING AN ULTRAVIOLET RADIATION-ABSORBING POLYMER - Ultraviolet radiation-absorbing polymers having a first pendant group that comprises an ultraviolet radiation-absorbing moiety and a second pendant group that comprises at least one siloxane linkage and/or an intermediate length carbon chain are disclosed. Personal care compositions including the ultraviolet radiation-absorbing polymer are provided. | 2009-12-31 |
20090324525 | FOUNDATION WITH HIGH CHROMATIC STABILITY AND METHOD TO OBTAIN SUCH FOUNDATION - Preparation of a foundation is described. The foundation is obtainable by mixing specific precursor emulsions, each of them having the complete composition of a foundation and containing a single pigment. The mixing directly provides the final foundation in the desired colour tone. Also described is a kit to obtain a foundation with improved stability, starting from the aforesaid emulsions. | 2009-12-31 |
20090324526 | Compositions comprising madecassoside and/or terminoloside and an arginine and/or a salt and/or a derivative thereof for inducing and/or stimulating the growth of human keratin fibers and/or preventing loss thereof - Cosmetic care compositions for human keratin fibers contain, formulated into a physiologically acceptable medium:
| 2009-12-31 |
20090324527 | HAIR CONDITIONING COMPOSITION CONTAINING BEHENYL TRIMETHYL AMMONIUM CHLORIDE, AND HAVING HIGHER YIELD POINT - Disclosed is a hair conditioning composition comprising: (a) a cationic surfactant being behenyltrimethylammonium chloride; (b) a high melting point fatty compound; and (c) an aqueous carrier; wherein the composition has a yield point of at least 5 Pa, and the yield point meeting the following mathematical expression: Y≧4.47X−5.10, wherein Y is yield point of the composition, X is a total amount (percentage by weigh of the composition) of the cationic surfactant and the high melting point fatty compound; and wherein the composition is substantially free of thickening polymers. The composition of the present invention effectively delivers conditioning benefits to hair. | 2009-12-31 |
20090324528 | HAIR CONDITIONING COMPOSITION CONTAINING A SALT OF STEARYL AMIDOPROPYL DIMETHYLAMINE, AND HAVING HIGHER YIELD POINT - Disclosed is a hair conditioning composition comprising: (a) a cationic surfactant being a salt of stearylamidopropyldimethylamine and 1-glutamic acid; (b) a high melting point fatty compound; and (c) an aqueous carrier; wherein the composition has a yield point of at least 5 Pa, and the yield point meeting the following mathematical expression: Y≧6.0×−28.5, wherein Y is yield point of the composition, X is a total amount (percentage by weigh of the composition) of the cationic surfactant and the high melting point fatty compound; and wherein the composition is substantially free of thickening polymers. The composition of the present invention effectively delivers conditioning benefits to hair. | 2009-12-31 |
20090324529 | HAIR CONDITIONING COMPOSITION CONTAINING A SALT OF BEHENYL AMIDOPROPYL DIMETHYLAMINE, AND HAVING HIGHER YIELD POINT - Disclosed is a hair conditioning composition comprising: (a) a cationic surfactant being a salt of behenylamidopropyldimethylamine and l-glutamic acid; (b) a high melting point fatty compound; and (c) an aqueous carrier; wherein the composition has a yield point of at least 5 Pa, and the yield point meeting the following mathematical expression: Y≧5.22X−17.82, wherein Y is yield point of the composition, X is a total amount (percentage by weigh of the composition) of the cationic surfactant and the high melting point fatty compound; and wherein the composition is substantially free of thickening polymers. The composition of the present invention effectively delivers conditioning benefits to hair. | 2009-12-31 |
20090324530 | HAIR CONDITIONING COMPOSITION HAVING HIGHER YIELD POINT AND HIGHER CONVERSION RATE OF FATTY COMPOUND TO GEL MATRIX - Disclosed is a hair conditioning composition comprising: (a) a cationic surfactant; (b) a high melting point fatty compound; and (c) an aqueous carrier; wherein the cationic surfactant, the high melting point fatty compound, and the aqueous carrier form a gel matrix; wherein the composition has from about 90% to about 100% of a conversion rate of the high melting point fatty compound to the gel matrix; and wherein the composition has a yield point of about 33 Pa or more. Also disclosed is a method of manufacturing of hair conditioning composition. The compositions of the present invention, and the compositions made by the method of the present invention, provide improved conditioning benefits, especially, improved wet conditioning benefits after rinsing and improved dry conditioning, while maintaining wet conditioning benefit before rinsing. | 2009-12-31 |
20090324531 | HAIR CONDITIONING COMPOSITION CONTAINING BEHENYL TRIMETHYL AMMONIUM METHOSULFATE, AND HAVING HIGHER YIELD POINT - Disclosed is a hair conditioning composition comprising: (a) a cationic surfactant being behenyltrimethylammonium methosulfate; (b) a high melting point fatty compound; and (c) an aqueous carrier; wherein the composition has a yield point of at least 15 Pa, and the yield point meeting the following mathematical expression: Y≧3.57 X | 2009-12-31 |
20090324532 | HAIR CONDITIONING COMPOSITION CONTAINING A SALT OF CETYL TRIMETHYL AMMONIUM CHLORIDE, AND HAVING HIGHER YIELD POINT - Disclosed is a hair conditioning composition comprising: (a) a cationic surfactant being cetyltrimethylammonium chloride; (b) a high melting point fatty compound; and (c) an aqueous carrier; wherein the composition has a yield point of at least 9 Pa, and the yield point meeting the following mathematical expression: Y≧3.50X−7.80, wherein Y is yield point of the composition, X is a total amount (percentage by weigh of the composition) of the cationic surfactant and the high melting point fatty compound; and wherein the composition is substantially free of thickening polymers. The composition of the present invention effectively delivers conditioning benefits to hair. | 2009-12-31 |
20090324533 | Bacillus amyloliquefaciens Strain - The composition of the invention comprises an aqueous mixture of an odor neutralizer component, an enhancer component for microbial activity, and a microbial component. This composition is designed to provide short- and long-term odor control effects and is environmentally friendly and economical for use. | 2009-12-31 |
20090324534 | SOLID EMULSION CONTAINING A LIQUID FATTY PHASE STRUCTURED WITH A POLYMER - The invention relates to a physiologically acceptable solid emulsion, especially a cosmetic emulsion, containing an aqueous phase and a liquid fatty phase, one dispersed in the other, said liquid fatty phase being structured with at least one polymer having a weight-average molecular mass ranging from 1000 to 30 000, comprising a) a polymer skeleton containing hydrocarbon-based repeating units provided with at least one heteroatom, and b) optionally functionalized pendent and/or terminal fatty chains containing from 12 to 120 carbon atoms and being linked to these units, the aqueous phase, the liquid fatty phase and the polymer forming a physiologically acceptable medium. This composition is especially in the form of a cast foundation, the application of which produces a natural, light, fresh deposit that shows good staying power over time. | 2009-12-31 |
20090324535 | MODIFIED MACROMOLECULE - The present invention relates to a macromolecule having a controlled terminal group stoichiometry, the macromolecule including a surface layer, at least one subsurface layer and at least two terminal groups including: a first terminal group which is a residue of a pharmaceutically active agent, a derivative thereof or precursor therefor; and a second terminal group selected to modify the pharmacokinetics of the pharmaceutically active agent and/or macromolecule, wherein terminal group stoichiometry refers to the number and type of terminal groups. | 2009-12-31 |
20090324536 | ANTIMICROBIAL POLYMERS AND COATINGS - Biocidal compounds have been synthesized and tested. These biocidal compounds have broad-spectrum efficacy and their biocidal properties are easily renewable. Illustrative examples of these biocidal compounds include N-halamine monomers and polymers and silver sulfadiazine polymers. These compounds can be used to add biocidal function to various materials and articles. | 2009-12-31 |
20090324537 | Polymeric Materials as Stomach Filler and Their Preparation - The present invention relates to swellable polymeric materials comprising a synthetic polymer, or copolymer, comprising a carboxylic group and a biopolymer that are suitable for bioapplications. Because of their ability to swell, the polymeric materials are suitable for use as stomach fillers for the treatment of being over weight or obese, or for inducing the feeling of being satiated. Methods for preparing the swellable polymeric materials comprising aqueous reaction systems are also disclosed. | 2009-12-31 |
20090324538 | Fusion molecules and IL-15 variants - The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making thesuch proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention. | 2009-12-31 |
20090324539 | CANCER TREATMENT COMBINING LYMPHODEPLETING AGENT WITH CTLs AND CYTOKINES - In a cancer treatment combining cell therapy with chemotherapy, autologous CD8 | 2009-12-31 |
20090324540 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS - Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well. | 2009-12-31 |
20090324541 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR VIRAL DISEASE - A prophylactic or therapeutic agent for a viral disease, characterized by combining 22β-methoxyolean-12-ene-3β,24(4β)-diol with an interferon as active ingredients is disclosed. The prophylactic or therapeutic agent of the present invention exhibits a high therapeutic effect by administering 22β-methoxyolean-12-ene-3β,24(4β)-diol and interferon as a combination thereof. | 2009-12-31 |
20090324542 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS IN THE TREATMENT OF DEMYELINATING DISORDERS - Disclosed are pharmaceutical combinations comprising at least one S1P receptor agonist, as well as a method for treating demyelinating diseases, e.g. multiple sclerosis or disorders associated therewith or Guillain-Barré syndrome, comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective amount of a) an S1P receptor agonist, and b) at least one co-agent shown to have clinical activity against at least one symptom of a demyelinating disease. | 2009-12-31 |
20090324543 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS - 2-amino-pyrido(3,2-d)pyrimidine derivatives with a specific substitution pattern on positions 4 and 6 of the core structure are useful in the treatment or prevention of an infection due to a virus from the Flaviviridae family, especially HCV, when administered to a patient in a therapeutically effective amount. | 2009-12-31 |
20090324544 | SUBSTITUTED CYCLIC PYRROLIDINE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2009-12-31 |
20090324545 | POLYMORPHIC FORMS OF (S)-1-TETRAHYDROFURAN-3-YL-3-(3-(3-METHOXY-4-(OXAZOL-5-YL)PHENYL)UREIDO)B- ENZYL CARBAMATE - The present invention relates to polymorphic forms of (S)-tetrahydrofuran-3-yl 3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)benzylcarbamate, processes therein, pharmaceutical compositions thereof, and uses therewith. | 2009-12-31 |
20090324546 | Method for modulating gene expression by modifying the cpg content - The invention relates to nucleic acid modifications for a directed expression modulation by the targeted insertion or removal of CpG dinucleotides. The invention also relates to modified nucleic acids and expression vectors. | 2009-12-31 |
20090324547 | Probiotic Oral Health Promoting Product - The present invention discloses an oral composition comprising a combination of probiotic bacteria selected from the group comprising | 2009-12-31 |
20090324548 | Vaccinia Virus Strains - The invention provides attenuated vaccinia virus vaccines that can be used in methods to prevent or treat small pox in patients, as well as methods of obtaining such vaccines. | 2009-12-31 |
20090324549 | PROTEINS AND/OR PEPTIDES FOR THE PREVENTION AND/OR TREATMENT OF NEURODEGENERATIVE DISEASES - Proteins and/or peptides originate from the gene which results from the retention of the intron 3 of the gene SMN identified in the gene bank with the access number AY876898 with use for the diagnosis and/or prevention and/or treatment of neurodegenerative diseases. | 2009-12-31 |
20090324550 | COMPOSITION AND METHOD FOR INHIBITION OF MICROORGANISMS - A composition and method for the inhibition of microorganisms. | 2009-12-31 |
20090324551 | TLR AGONISTS - The present invention provides for TLR agonist conjugates (compounds) and compositions, as well as methods of using them. The compounds of the invention are broad-spectrum, long-lasting, and non-toxic combination of synthetic immunostimulatory agents, which are useful for activating the immune system of a mammal, preferably a human and can help direct the pharmacophore to the receptor within the endosomes of target cells and enhance the signal transduction induced by the pharmacophore. | 2009-12-31 |
20090324552 | CONTROLLED RELEASE CYTOTOXIC AGENT COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS - Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with cytotoxic agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s). | 2009-12-31 |
20090324553 | Chimeric Viral Envelopes - The invention relates to chimeric polytropic viral envelope polypeptides and uses thereof, as well as to polynucleotides encoding said chimeric polypeptides and constructs comprising said polypeptides and/or polynucleotides. The invention also relates to chimeric retroviral envelope polypeptides, polynucleotides and vectors encoding said chimeric retroviral envelope polypeptides, virus particles and cells harbouring said chimeric envelope polypeptides. Said chimeric polypeptide comprise an envelope polypeptide, or fragment thereof, and a polypeptide sequence of a receptor binding region, ligand or polypeptide sequence of a ligand binding region, and optionally a linker sequence. The invention include methods of targeting receptors, methods of treatment and methods for delivery of agents using said chimeric retroviral envelope polypeptides. The invention is applicable for directed targeting and controlled fusion of virus particles with other cellular membranes. | 2009-12-31 |
20090324554 | METHOD FOR INHIBITING OR TREATING A DISEASE ASSOCIATED WITH INTRACELLULAR FORMATION OF PROTEIN FIBRILLAR OR AGGREGATES - A therapeutic agent which carries a peptide sequence containing a mammalian cell adhesion sequence can be used to inhibit or treat diseases associated with intracellular formation of protein fibrillar inclusions or aggregates, to inhibit the intracellular formation of protein fibrillar inclusions or aggregates, and to disaggregate pre-formed intracellular protein fibrillar inclusions or aggregates. Filamentous bacteriophage which displays a non-filamentous bacteriophage RGD cell adhesion sequence on its surface, but not an antibody or non-filamentous bacteriophage antigen other than said RGD cell adhesion sequence, is a preferred embodiment of such a therapeutic agent. | 2009-12-31 |
20090324555 | Neural Stem Cells - Subject of the invention is a method for generating neural stem cells in vitro, wherein dental progenitor cells are isolated from soft tissue of tooth or wisdom tooth and cultivated until they form primary spheres which are then dissociated into single cells. These single cells are cultivated until they form spheroids and the spheroid-forming cells are separated to obtain neural stem cells. | 2009-12-31 |
20090324556 | Mutated immunogenic peptides derived from R9M, polynucleotides coding for same and therapeutic uses thereof - The invention concerns the optimization of the wild R9M peptide and the use of the resulting peptides for therapeutic vaccination and/or preventive vaccination against leukaemia in humans. More particularly, the invention concerns mutated immunogenic peptides derived from the human TEL/AML1 fusion protein comprising the wild R9M peptide sequence Arg-Ile-Ala-Glu-Czs-Ile-Leu-Gly-Met. The invention also concerns polynucleotides coding for the mutated R9M immunogenic peptides, cellular expression vectors comprising nucleic acid sequences expressing the mutated R9M immunogenic peptides and polyclonal or monoclonal antibodies capable of being fixed on at least one of said peptides/polynucleotides. The invention further concerns the use of said peptides, polynucleotides and/or antibodies for preparing vaccines, anti-tumoral medicines and compositions and for in vitro and in vivo stimulation of the immune response in humans. | 2009-12-31 |
20090324557 | METHOD TO INDUCE AND EXPAND THERAPEUTIC ALLOANTIGEN-SPECIFIC HUMAN REGULATORY T CELLS IN LARGE-SCALE - Methods for inducing, expanding, and/or generating alloantigen-specific regulatory T cells. Alloantigen-specific regulatory T cells can be induced, expanded, and/or generated from naive CD4 | 2009-12-31 |
20090324558 | Transdiscal administration of cycline compounds - The present invention relates to administering a doxycycline compound into a diseased intervertebral disc. | 2009-12-31 |
20090324559 | METHODS AND PLATFORMS FOR DRUG DISCOVERY - The present invention involves methods for identifying an agent that corrects a phenotype associated with a health condition or a predisposition for a health condition. The invention also involves methods for identifying a diagnostic cellular phenotype, determining the risk of a health condition in a subject, methods for reducing the risk of drug toxicity in a human subject, and methods for identifying a candidate gene that contributes to a human disease. The invention also discloses human induced pluripotent stem cell lines. | 2009-12-31 |
20090324560 | METHOD FOR PREPARATION OF CARTILAGE CELL - Chondrocytes are prepared from perichondrocytes. | 2009-12-31 |
20090324561 | Cells exhibiting neuronal progenitor cell characteristics and methods of making them - Disclosed are cells exhibiting neuronal progenitor cell characteristics, and methods of making them from marrow adherent stem cells by regulating cellular pathways in the marrow adherent stem cells that are associated with glial transdifferentiation of the marrow adherent stem cells. | 2009-12-31 |
20090324562 | Defensin Proteins - This invention relates to the novel proteins, termed INSP108 and INSP109, herein identified as members of the defensin family of proteins and to the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease. | 2009-12-31 |
20090324563 | MOISTURIZER - The present invention provides a moisturizer comprising heat-killed cells of | 2009-12-31 |
20090324564 | MICROORGANISM CAPABLE OF CONTROLLING PLANT DISEASES AND PLANT DISEASE-CONTROLLING AGENT USING THE MICROORGANISM - The object of the present invention is to provide a microorganism which places little burden on the environment, shows an extremely low possibility of a resistant pathogenic bacterium to emerge, and has a superior controlling ability against various plant diseases (in particular, soft rot and canker of leaf and root vegetables); a plant disease controlling agent containing the microorganism; and a method for controlling plant diseases comprising applying the plant disease controlling agent to the plant and/or the grove soil thereof. A plant disease controlling agent is used which contains a bacterial cell of | 2009-12-31 |
20090324565 | A Colicinogenic Strain of E. Coli - Described herein is the isolation of colicin-producing strains of | 2009-12-31 |
20090324566 | T-Cell Receptor and Nucliec Acid Encoding the Receptor - A polypeptide comprising a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 5 of Sequence Listing or a polypeptide consisting of an amino acid sequence having deletion, addition, insertion or substitution of one to several amino acid residues in the sequence, the polypeptide being capable of constituting an HLA-A24-restricted, MAGE-A4 | 2009-12-31 |
20090324567 | Leukocyte Cell Banks - The invention relates to a novel form of leukapheresis (isolated leukapheresis), to processes and apparatus for carrying out isolated leukapheresis, to leukocyte cell banks created thereby and to various forms of therapy based thereon. | 2009-12-31 |
20090324568 | Colonic Delivery of Adsorbents - Orally administrable, site-specific (colonic), particulate delivery systems including adsorbents are disclosed. When delivered specifically to the colon, they can remove various substances present in, or as they reach, the colon. Methods of treatment using the delivery systems, and methods of preparing the delivery systems, are also disclosed. The particulate delivery systems are based on adsorbent matrices encapsulated into and/or onto particles, which selectively deliver the adsorbents to the colon. Representative drug delivery devices include pectin beads, which can optionally be crosslinked with metal ions such as zinc and/or calcium. The delivery system protects the adsorbent and prevents its adsorbing effect in the upper gastro-intestinal (GI) tract. When the particles are made from pectin, and the beads are administered to the colon, specific pectinolytic enzymes in the colon degrade the pectin, allowing the adsorbent to be released and to be fully active. Antibiotics, toxins, and other absorbable substances present in the colon will then be inactivated by adsorption into or onto the adsorbent. | 2009-12-31 |
20090324569 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS - The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders. The compounds have general formula I: | 2009-12-31 |
20090324570 | Photostabilization of Retinoids with Alkoxycrylene Compounds - The photostabilizing electronic excited state energy—particularly singlet state energy from retinoid compounds—has been found to be readily transferred to (accepted by) α-cyanodiphenylacrylate compounds having an alkoxy radical in the four (para) position (hereinafter “alkoxycrylenes”) on one of the phenyl rings having the formula (I): | 2009-12-31 |
20090324571 | USE OF BACTERIAL AMYLASES IN FEED FOR BOVINE ANIMALS - The invention relates to the use of at least one bacterial amylase in feed for ruminant animals of the subfamily Bovinae in particular for improving milk yield, apparent digestibility of the diet fed, feedstuff dry matter disappearance, weight gain, and/or Feed Conversion Ratio (FCR). Examples of bovine animals are dairy cows and beef cattle. The invention also relates to the use of such amylases in feed and feed additives such as premix, concentrates and total mixed ration (TMR). The amylase may be used in combination with cellulase for improving milk yield and/or back fat thickness. Preferred amylases are derived from | 2009-12-31 |
20090324572 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SYMPTOMS OF WILLIAMS SYNDROME - A therapeutic composition for the treatment of the symptoms of Williams Syndrome and the method for preparing the therapeutic agents is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic composition may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as a biomarker for the presence of Williams Syndrome, or the likelihood of an individual to develop Williams Syndrome is disclosed. | 2009-12-31 |
20090324573 | Pharmaceutical Composition Comprising P43 Protein for the Treatment of Gastric Adenocarcinoma - A pharmaceutical composition for the treatment of gastric adenocarcinoma is provided, wherein the pharmaceutical composition comprises p43 protein and pharmaceutically acceptable carriers, and does not comprise paclitaxel. A use of p43 protein for the treatment of gastric adenocarcinoma is also provided. | 2009-12-31 |
20090324574 | Esterases and Related Nucleic Acids and Methods - The invention provides hydrolases, polynucleotides encoding them, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides, e.g., enzymes, having a hydrolase activity, e.g., an esterase, acylase, lipase, phospholipase (e.g., phosphplipase A, B, C and D activity, patatin activity, lipid acyl hydrolase (LAH) activity) or protease activity, including thermostable and thermotolerant hydrolase activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The hydrolase activities of the polypeptides and peptides of the invention include esterase activity, lipase activity (hydrolysis of lipids), acidolysis reactions (to replace an esterified fatty acid with a free fatty acid), transesterification reactions (exchange of fatty acids between triglycerides), ester synthesis, ester interchange reactions, phospholipase activity and protease activity (hydrolysis of peptide bonds). The polypeptides of the invention can be used in a variety of pharmaceutical, agricultural and industrial contexts, including the manufacture of cosmetics and nutraceuticals. In another aspect, the polypeptides of the invention are used to synthesize enantiomerically pure chiral products. | 2009-12-31 |
20090324575 | LYSOSOMAL PHOSPHOLIPASE A2 (LPLA2) ACTIVITY AS A DIAGNOSTIC AND THERAPEUTIC TARGET FOR IDENTIFYING AND TREATING SYSTEMIC LUPUS ERYTHEMATOSIS - The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus. | 2009-12-31 |
20090324576 | PHAGE DERIVED ANTIMICROBIAL ACTIVITIES - The present invention provides methods and compositions to reduce growth of microbial colonies, including infections, and includes therapeutic compositions, methods for treatment of infections, and methods for identifying additional such compositions. | 2009-12-31 |